Brendan Halloran

Associate Professor, Faculty of Medicine & Dentistry - Medicine Dept

Contact Overview Publications

Contact

Associate Professor, Faculty of Medicine & Dentistry - Medicine Dept

Email: brendan@ualberta.ca
Phone: (780) 492-8691

Overview

Area of Study / Keywords

About

Other positions I currently hold are:

Clinical Co-Director - Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR)
Program Director - Inflammatory Bowel Disease Fellowship Training Program
Co-Director - Small Bowel Endoscopy Program

Research

Improving treatment of patients with inflammatory bowel diseases (IBD)

Application of microarray technology to predict the outcome of IBD as well as a patient's response to therapies, such as infliximab, adalimumab, and vedolizumab.

Small bowel endoscopy

Double-balloon endoscopy is a relatively new technology that my team is assessing for the management of patients with Crohn's disease of the small bowel.
Imaging of the entire intestinal tract provides insight into how the individual is responding to therapy and can inform treatment modifications.

Epstein-Barr virus in IBD

Health economic assessments of biologic therapies for the treatment of IBD

Featured Publications

A116 Clinical outcomes of patients undergoing balloon-assisted endoscopy for suspected small bowel bleeding

Canadian Digestive Disease Week. 2022 February; 10.1093/jcag/gwab049.115

A31 Outcomes of patients undergoing repeat videocapsule endoscopy (VCE) presenting with obscure gastrointestinal bleeding (OGIB)

Canadian Digestive Disease Week. 2022 February; 10.1093/jcag/gwab049.030

A93 Usefulness of a novel smartphone app in gastrointestinal endoscopy to track procedure numbers and therapeutic interventions

Canadian Digestive Disease Week. 2022 February; 10.1093/jcag/gwab049.092

Breastfeeding patterns in mothers with inflammatory bowel disease: A pilot prospective longitudinal study

Tandon P, Lee E, Jogendran R, Kroeker K, Dieleman L, Halloran B, Wong K, Berga K, Huang V

INFLAMMATORY BOWEL DISEASES. 2022 January; 10.1093/ibd/izab354

Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial

Balram B., Joshi H., Wong K., Kroeker K.I., Dieleman L.A., Halloran B.P., Baumgart D.C., Peerani F.

DIGESTIVE DISEASES AND SCIENCES. 2021 November; 66 (11):3985-3992 10.1007/s10620-020-06704-6

Double-Balloon Endoscopy in Crohn Disease: A Tertiary Referral Center Experience

Halloran B.P., Jamil L.H., Lo S.K., Reeson M., Vasiliauskas E.A., Targan S., Ippoliti A., Mann N.K., Melmed G.Y.

INFLAMMATORY BOWEL DISEASES. 2021 August; 27 (8):1248-1255 10.1093/ibd/izaa287

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab

Hu A., Kotze P.G., Burgevin A., Tan W., Jess A., Li P.S., Kroeker K., Halloran B., Panaccione R., Peyrin-Biroulet L., Ma C., Ananthakrishnan A.N.

Clinical Gastroenterology and Hepatology. 2021 July; 19 (7):1366-1376.e2 10.1016/j.cgh.2020.07.012

Using Patient Completed Screening Tools to Predict Risk of Malnutrition in Patients with Inflammatory Bowel Disease

Taylor L.M., Eslamparast T., Farhat K., Kroeker K., Halloran B., Shommu N., Kumar A., Fitzgerald Q., Gramlich L., Abraldes J.G., Tandon P., Raman M.

Crohn's and Colitis 360. 2021 July; 3 (3) 10.1093/crocol/otab043

Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease

Tandon P., Lee E.Y., Maxwell C., Hitz L., Ambrosio L., Dieleman L., Halloran B., Kroeker K., Huang V.M.

DIGESTIVE DISEASES AND SCIENCES. 2021 May; 66 (5):1639-1649 10.1007/s10620-020-06381-5

PREBIOTIC �-FRUCTANS PREVENT SUBCLINICAL INTESTINAL INFLAMMATION IN ULCERATIVE COLITIS PATIENTS WHO ARE IN CLINICAL REMISSION

Gastroenterology. 2021 May; 10.1016/S0016-5085(21)01040-4

SHORTER DISEASE DURATION IN PATIENTS WITH CROHN'S DISEASE IS ASSOCIATED WITH HIGHER RATES OF REMISSION WITH USTEKINUMAB

Gastroenterology. 2021 May; 10.1016/S0016-5085(21)02383-0

THE REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF CROHN'S DISEASE

Gastroenterology. 2021 May; 10.1016/S0016-5085(21)01043-X

MAJORITY OF INFLAMMATORY BOWEL DISEASE PATIENTS WITH RECURRENT CLOSTRIDIOIDES INFECTION DO NOT REQUIRE FECAL MICROBIOTA TRANSPLANTATION

Journal of the Canadian Association of Gastroenterology. 2021 March;

Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial

Balram B., Joshi H., Wong K., Kroeker K.I., Dieleman L.A., Halloran B.P., Baumgart D.C., Peerani F.

DIGESTIVE DISEASES AND SCIENCES. 2020 November; 10.1007/s10620-020-06704-6

Double-Balloon Endoscopy in Crohn Disease: A Tertiary Referral Center Experience

Halloran B.P., Jamil L.H., Lo S.K., Reeson M., Vasiliauskas E.A., Targan S., Ippoliti A., Mann N.K., Melmed G.Y.

Inflammatory Bowel Diseases. 2020 November; 27 (8):1248-1255 10.1093/ibd/izaa287